Persona Revision Knee System Outcomes
Launched by ZIMMER BIOMET · Mar 25, 2021
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
The Persona Revision Knee System Outcomes trial is studying a new knee replacement system to see how well it works, its benefits, and its safety for patients who have had knee surgeries before. The trial is open to men and women aged 18 and older who have specific knee conditions, like arthritis or joint injuries. To participate, patients need to agree to follow the study rules and provide consent. They should have a particular score that indicates their knee function is not doing well.
Participants in this study can expect to receive the Persona Revision Knee System and will be monitored for their recovery and overall knee performance over time. It's important to note that people with certain infections, significant bone issues, or those who are pregnant cannot join the trial. This study aims to gather valuable information that could help improve knee surgeries in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male or female of at least 18 years of age at the time of screening.
- • 2. Signed an institutional review board approved informed consent.
- • 3. Willingness and ability to comply with the study procedures and visit schedules and ability to understand and follow oral and written post-operative care instructions.
- 4. Previous medical diagnosis/ history of at least one of the following conditions requiring treatment using the Persona Revision Knee System within a pre-specified study variant configuration (cohort), in accordance with the instructions for use (IFU):
- • 1. Rheumatoid arthritis, osteoarthritis, traumatic arthritis or polyarthritis
- • 2. Collagen disorders, and/or avascular necrosis of the femoral condyle
- • 3. Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy
- • 4. Moderate valgus, varus, or flexion deformities
- • 5. The salvage of previously failed surgical attempts or for a knee in which satisfactory stability in flexion cannot be obtained at the time of surgery
- • 5. A pre-operative Knee Society Knee Score (objective assessment) ≤ 80.
- Exclusion Criteria:
- • 1) Presence of clinically observed active or suspected latent infection in the affected joint at the time of procedure.
- • 3) Presence of of local/systemic/distant focal infection that may affect or hematogenously spread to the prosthetic joint.
- • 4) Skeletal immaturity or insufficient bone stock on femoral or tibial surfaces which cannot provide adequate support and/or fixation to the prosthesis.
- • 5) Diagnosed with neuropathic arthropathy, osteoporosis, or any loss of musculature or neuromuscular disease that compromises the affected limb.
- • 6) Presence of a stable, painless arthrodesis in a satisfactory functional position in the affected joint.
- • 7) Severe instability of the affected joint secondary to the absence of collateral ligament integrity.
- 8) Diagnosis of rheumatoid arthritis in conjunction with any of the following at the time of screening:
- • 1. An ulcer of the skin
- • 2. History of recurrent breakdown of the skin
- • 3. Use of steroids
- • 9) Patient requires simultaneous bilateral knee surgery for treatment of diagnosed condition.
- • 10) Pregnant or women planning to become pregnant during the time they will be participating in the study.
- • 11) Any documented clinically significant degree of cognitive impairment or other condition, finding, or psychiatric illness at screening which, in the opinion of the Investigator, could compromise patient safety or interfere with the assessment of the safety and treatment effects of the study procedure.
- • 12) Any patient who is institutionalized, or with a known drug or alcohol dependence currently or within the last year.
About Zimmer Biomet
Zimmer Biomet is a leading global medical technology company specializing in the design, development, and manufacturing of innovative orthopedic and surgical products. With a commitment to enhancing patient outcomes, Zimmer Biomet focuses on advancing musculoskeletal health through a broad range of solutions, including joint reconstruction, surgical instrumentation, and dental implants. The company emphasizes research and development, conducting numerous clinical trials to evaluate the safety and effectiveness of its products, while fostering collaboration with healthcare professionals to address the evolving needs of patients and providers alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cleveland, Ohio, United States
Fayetteville, Arkansas, United States
Rochester, Michigan, United States
Little Rock, Arkansas, United States
Fresno, California, United States
Superior, Colorado, United States
Evansville, Indiana, United States
Granger, Indiana, United States
Louisville, Kentucky, United States
Columbia, Missouri, United States
Chester, New Jersey, United States
Oregon City, Oregon, United States
Lancaster, Pennsylvania, United States
Bloomington, Minnesota, United States
Southfield, Michigan, United States
Wauwatosa, Wisconsin, United States
Patients applied
Trial Officials
Charles Jaggard
Study Director
Zimmer Biomet
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials